# LOQTORZI (toripalimab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/toripalimab

> The FDA approved LOQTORZI (toripalimab), sponsored by Coherus Oncology, Inc. (CHRS), on Jan 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | LOQTORZI (toripalimab) |
| Codes |  |
| Sponsor | Coherus Oncology, Inc. (CHRS) https://sec-api.dev/companies/chrs/catalysts |
| Indications | with recurrent, unresectable, or metastatic npc with disease progression, with recurrent unresectable, or metastatic npc with disease progression, with recurrent, unresectable, or metastatic npc with disease |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### October 27, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: with recurrent, unresectable, or metastatic NPC with disease progression.
- First seen 2025-03-17, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-111484): "On October 27, 2023, we announced that LOQTORZI was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease" https://www.sec.gov/Archives/edgar/data/1512762/000110465925111484/chrs-20251113xex99d1.htm
- SEC Form 10-Q (accession 0001104659-26-124572): "On October 27, 2023, we announced that LOQTORZI was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy." https://www.sec.gov/Archives/edgar/data/1512762/000110465926124572/chrs-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-091262): "On October 27, 2023, we announced that LOQTORZI was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy." https://www.sec.gov/Archives/edgar/data/1512762/000110465926091262/chrs-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-058703): "On October 27, 2023, we announced that LOQTORZI was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy." https://www.sec.gov/Archives/edgar/data/1512762/000110465926058703/chrs-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-025308): "On October 27, 2023, we announced that LOQTORZI was approved by the U.S. Food and Drug Administration ("FDA") in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma, and as monotherapy for the treatment of adults with recurrent unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy." https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-025308): "On October 27, 2023, we announced that LOQTORZI was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy." https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-025308): "On October 27, 2023, we announced that LOQTORZI was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC ("RM-NPC"), and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy." https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-025308): "On October 27, 2023, we announced that LOQTORZI was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy." https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-111484): "On October 27, 2023, LOQTORZI was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy." https://www.sec.gov/Archives/edgar/data/1512762/000110465925111484/chrs-20251113xex99d1.htm
- SEC Form 10-Q (accession 0001104659-25-107852): "On October 27, 2023, we announced that LOQTORZI was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy." https://www.sec.gov/Archives/edgar/data/1512762/000110465925107852/chrs-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010803): "On October 27, 2023, we announced that LOQTORZI was approved by the FDA in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy." https://www.sec.gov/Archives/edgar/data/1512762/000155837025010803/chrs-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007418): "On October 27, 2023, the Company announced that LOQTORZI was approved by the U.S. Food and Drug Administration ("FDA") in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma ("NPC"), and as monotherapy for the treatment of adults with recurrent unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy." https://www.sec.gov/Archives/edgar/data/1512762/000155837025007418/chrs-20250331x10q.htm

### Jan 2024: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-03-17, last confirmed 2025-03-17.
- SEC Form 10-K (accession 0001558370-25-003126): "Following the FDA approval of LOQTORZI for NPC, the commercial launch commenced in January 2024 with our existing Oncology commercial and medical affairs teams." https://www.sec.gov/Archives/edgar/data/1512762/000155837025003126/chrs-20241231x10k.htm

### mid-2026: interim data readout

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2025-08-07, last confirmed 2026-05-11.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-058666): "The Phase 1b tagmokitug/toripalimab combination dose optimization studies in 2L HNSCC and 2L upper GI adenocarcinoma cancers are underway, with initial data readouts expected in mid-2026." https://www.sec.gov/Archives/edgar/data/1512762/000110465926058666/chrs-20260511xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-025293): "The Phase 1b tagmokitug/toripalimab combination dose optimization studies in 2L HNSCC and 2L upper GI adenocarcinoma cancers are underway, with initial data readouts expected in mid-2026." https://www.sec.gov/Archives/edgar/data/1512762/000110465926025293/chrs-20260309xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-107780): "Phase 1b CHS-114/toripalimab combination dose optimization studies in 2L HNSCC and 2L gastric cancers are underway, with initial data readouts for HNSCC expected in 1H 2026." https://www.sec.gov/Archives/edgar/data/1512762/000110465925107780/chrs-20251106xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010802): "Phase 1b CHS-114/toripalimab combination dose optimization studies in 2L head and neck (HNSCC) and 2L gastric cancers are underway, with initial data readouts expected in 1H 2026." https://www.sec.gov/Archives/edgar/data/1512762/000155837025010802/chrs-20250807xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-058666): "A Phase 1b/2a study evaluating tagmokitug/toripalimab combination in 4L+ colorectal cancer is enrolling patients and initial data is expected in 2H 2026." https://www.sec.gov/Archives/edgar/data/1512762/000110465926058666/chrs-20260511xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-025293): "A Phase 1b/2a study evaluating tagmokitug/toripalimab combination in 4L+ colorectal cancer is enrolling patients and initial data is expected in 2H 2026." https://www.sec.gov/Archives/edgar/data/1512762/000110465926025293/chrs-20260309xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-107780): "A Phase 1b/2a study evaluating CHS-114/toripalimab combination in 4L+ colorectal cancer is enrolling patients and initial data is expected in 2H 2026." https://www.sec.gov/Archives/edgar/data/1512762/000110465925107780/chrs-20251106xex99d1.htm

### Q2 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2024-12-03, last confirmed 2025-11-06.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007410): "The Company initiated a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L HNSCC in Q1 2025 with a first data readout expected in Q2 2026." https://www.sec.gov/Archives/edgar/data/1512762/000155837025007410/chrs-20250512xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007410): "The Company initiated a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L gastric cancer in Q1 2025 with a first data readout expected in Q2 2026." https://www.sec.gov/Archives/edgar/data/1512762/000155837025007410/chrs-20250512xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-107780): "A Phase 1b study evaluating the CHS-114/toripalimab combination, with and without chemotherapy, in 1L and 2L esophageal squamous cell carcinoma (ESCC), respectively, is underway with a first data readout expected in mid-2026." https://www.sec.gov/Archives/edgar/data/1512762/000110465925107780/chrs-20251106xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010802): "A Phase 1b study evaluating the CHS-114/toripalimab combination, with and without chemotherapy, in 1L and 2L esophageal squamous cell carcinoma (ESCC), respectively, is underway with a first data readout expected in 1H 2026." https://www.sec.gov/Archives/edgar/data/1512762/000155837025010802/chrs-20250807xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-002595): "Initiate a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L gastric cancer in Q1 2025 with a first data readout expected in Q2 2026." https://www.sec.gov/Archives/edgar/data/1512762/000155837025002595/chrs-20250310xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-124881): "- Initiate a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L gastric cancer in Q1 2025 with a first data readout expected in Q2 2026." https://www.sec.gov/Archives/edgar/data/1512762/000110465924124881/tm2429853d1_ex99-1.htm

### 2H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2026-03-09, last confirmed 2026-05-11.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-058666): "A Phase 1b study evaluating the tagmokitug/toripalimab combination, with and without chemotherapy, in 1L and 2L esophageal squamous cell carcinoma (ESCC), respectively, is underway with a first data readout expected in 2H 2026." https://www.sec.gov/Archives/edgar/data/1512762/000110465926058666/chrs-20260511xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-025293): "A Phase 1b study evaluating the tagmokitug/toripalimab combination, with and without chemotherapy, in 1L and 2L esophageal squamous cell carcinoma (ESCC), respectively, is underway with a first data readout expected in 2H 2026." https://www.sec.gov/Archives/edgar/data/1512762/000110465926025293/chrs-20260309xex99d1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/toripalimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LOQTORZI (toripalimab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/toripalimab

```bibtex
@misc{secapidev_pdufa_toripalimab_20261116,
  title        = {LOQTORZI (toripalimab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/toripalimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_toripalimab_20261116","title":"LOQTORZI (toripalimab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/toripalimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
